* Biogen to present at J.P. Morgan healthcare conference
* Says Tysabri sales passed $1 bln mark in 2009
* Has filed for European approval of Fampridine-PR
BOSTON, Jan 10 (Reuters) - Biogen Idec Inc (BIIB.O) said on Tuesday that sales of its multiple sclerosis drug Tysabri exceeded $1 billion in 2009, and the number of patients treated rose 30 percent.
The Cambridge, Massachusetts-based biotech company also said it has filed for approval in Europe of Fampridine Prolonged Release, or Fampridine-PR, an oral therapy to improve walking ability in patients with multiple sclerosis.
Biogen made its statements ahead of a presentation at the J.P. Morgan healthcare conference.
Jim Mullen, the company’s chief executive, said in a statement that it estimates the number of patients taking Tysabri, its biggest growth driver, were 48.800 worldwide at the end of December.
Tysabri is co-marketed with Elan Corp Plc ELN.I of Ireland.
The company said that in the first half of 2010 it expects to initiate a registrational trial of its experimental treatment for hemophilia B.
Sales of Tysabri have been curbed by concerns over its link with progressive multifocal leukoencephalopathy, or PML, a viral infection of the brain.
Biogen said the risk of PML increases with duration of use. (Reporting by Toni Clarke, editing by Gerald E. McCormick)